JP7094566B2 - Ａｌｋ阻害剤としてのアミノピリミジン類 - Google Patents

Ａｌｋ阻害剤としてのアミノピリミジン類 Download PDF

Info

Publication number
JP7094566B2
JP7094566B2 JP2019511664A JP2019511664A JP7094566B2 JP 7094566 B2 JP7094566 B2 JP 7094566B2 JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019511664 A JP2019511664 A JP 2019511664A JP 7094566 B2 JP7094566 B2 JP 7094566B2
Authority
JP
Japan
Prior art keywords
phenyl
diamine
isopropoxy
pyrimidine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528307A (ja
JP2019528307A5 (cg-RX-API-DMAC7.html
Inventor
ワン シャオメン
チエンヨン チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2019528307A publication Critical patent/JP2019528307A/ja
Publication of JP2019528307A5 publication Critical patent/JP2019528307A5/ja
Priority to JP2022096630A priority Critical patent/JP2022120151A/ja
Application granted granted Critical
Publication of JP7094566B2 publication Critical patent/JP7094566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019511664A 2016-08-29 2017-08-28 Ａｌｋ阻害剤としてのアミノピリミジン類 Active JP7094566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096630A JP2022120151A (ja) 2016-08-29 2022-06-15 Ａｌｋ阻害剤としてのアミノピリミジン類

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096630A Division JP2022120151A (ja) 2016-08-29 2022-06-15 Ａｌｋ阻害剤としてのアミノピリミジン類

Publications (3)

Publication Number Publication Date
JP2019528307A JP2019528307A (ja) 2019-10-10
JP2019528307A5 JP2019528307A5 (cg-RX-API-DMAC7.html) 2020-10-01
JP7094566B2 true JP7094566B2 (ja) 2022-07-04

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511664A Active JP7094566B2 (ja) 2016-08-29 2017-08-28 Ａｌｋ阻害剤としてのアミノピリミジン類
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Ａｌｋ阻害剤としてのアミノピリミジン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Ａｌｋ阻害剤としてのアミノピリミジン類

Country Status (11)

Country Link
US (2) US10709705B2 (cg-RX-API-DMAC7.html)
EP (2) EP3504203B1 (cg-RX-API-DMAC7.html)
JP (2) JP7094566B2 (cg-RX-API-DMAC7.html)
KR (1) KR102530871B1 (cg-RX-API-DMAC7.html)
CN (2) CN109715620B (cg-RX-API-DMAC7.html)
AU (2) AU2017319135B2 (cg-RX-API-DMAC7.html)
IL (1) IL264638B (cg-RX-API-DMAC7.html)
MX (2) MX389265B (cg-RX-API-DMAC7.html)
NZ (1) NZ751713A (cg-RX-API-DMAC7.html)
SG (2) SG10201914030UA (cg-RX-API-DMAC7.html)
WO (1) WO2018044767A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020024825A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of fak/alk/ros1 inhibitor and egfr inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
TWI769470B (zh) * 2019-06-25 2022-07-01 大陸商蘇州亞盛藥業有限公司 用於治療疾病的fak抑制劑和btk抑制劑的組合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022063220A1 (en) * 2020-09-25 2022-03-31 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
US20240316051A1 (en) * 2021-04-19 2024-09-26 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof
JP2024544576A (ja) * 2021-12-09 2024-12-03 オンコビクス・カンパニー・リミテッド 癌細胞成長への抑制効果を示す新規ヘテロ環置換ピリミジン誘導体及びそれを含む医薬組成物
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
AU2024210803A1 (en) 2023-01-20 2025-07-03 Ascentage Pharma (Suzhou) Co., Ltd. Crystal form of alk inhibitor or salt and solvate thereof, preparation method therefor, and use thereof
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504646A (ja) 2011-02-02 2014-02-24 アイアールエム・リミテッド・ライアビリティ・カンパニー Ａｌｋ阻害剤の使用方法
WO2015081813A1 (zh) 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SI2287156T1 (sl) 2003-08-15 2013-09-30 Novartis Ag 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema
CN100584832C (zh) * 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
KR101238585B1 (ko) 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2011315831B2 (en) 2010-10-14 2015-01-22 Takeda Pharmaceutical Company Limited Methods for inhibiting cell proliferation in EGFR-driven cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504646A (ja) 2011-02-02 2014-02-24 アイアールエム・リミテッド・ライアビリティ・カンパニー Ａｌｋ阻害剤の使用方法
WO2015081813A1 (zh) 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
CN109715620A (zh) 2019-05-03
WO2018044767A2 (en) 2018-03-08
SG11201901251SA (en) 2019-03-28
NZ751713A (en) 2022-07-01
AU2021203098A1 (en) 2021-06-10
IL264638B (en) 2021-08-31
CN109715620B (zh) 2022-05-06
US11110090B2 (en) 2021-09-07
EP4001273A2 (en) 2022-05-25
CA3033223A1 (en) 2018-03-08
CN115043821A (zh) 2022-09-13
US20190175595A1 (en) 2019-06-13
JP2019528307A (ja) 2019-10-10
US10709705B2 (en) 2020-07-14
MX389265B (es) 2025-03-20
AU2021203098B2 (en) 2023-05-25
MX2019002393A (es) 2019-07-08
EP3504203A2 (en) 2019-07-03
AU2017319135A1 (en) 2019-04-04
JP2022120151A (ja) 2022-08-17
AU2017319135B2 (en) 2021-03-18
MX2022000376A (es) 2022-02-10
SG10201914030UA (en) 2020-03-30
CN115043821B (zh) 2024-08-06
BR112019003897A2 (pt) 2019-05-21
EP3504203B1 (en) 2022-09-28
EP4001273A3 (en) 2022-08-24
US20200330464A1 (en) 2020-10-22
KR20190039760A (ko) 2019-04-15
KR102530871B1 (ko) 2023-05-09
WO2018044767A3 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP7094566B2 (ja) Ａｌｋ阻害剤としてのアミノピリミジン類
US11192898B2 (en) MDM2 protein degraders
JP7072519B2 (ja) Ｂｅｔタンパク質分解剤
CN110914265B (zh) 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
US20210115018A1 (en) Piperidine compounds as covalent menin inhibitors
CN110294750A (zh) 作为alk抑制剂的5,6-二氢-11h-吲哚并[2,3-b]喹啉-11-酮化合物
AU2017363161B2 (en) 5,6-dihydro-11H-indolo[2,3-b]quinolin-11-ones as ALK inhibitors
HK40077976A (en) Aminopyrimidines as alk inhibitors
CA3033223C (en) Aminopyrimidines as alk inhibitors
HK40077976B (zh) 作为alk抑制剂的氨基嘧啶
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40007649B (en) Aminopyrimidines as alk inhibitors
HK40007649A (en) Aminopyrimidines as alk inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40012150A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors
BR112019003897B1 (pt) Compostos de aminopirimidinas como inibidores de alk, composição farmacêutica bem como seus usos
HK40013399A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220615

R150 Certificate of patent or registration of utility model

Ref document number: 7094566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250